📰 Urologic Sciences News
Urologic Sciences News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Urologic Sciences. Real-time updates on events, politics, business and more.
May 3, 2024
VANCOUVER, May 2, 2024—Quantum in silicon company Photonic today announced it is adding to its executive leadership team in the areas of research and [...]
April 9, 2024
VANCOUVER, British Columbia, April 09, 2024 -- Rakovina Therapeutics Inc. , , a biopharmaceutical company dedicated to improving the lives of cancer patients through the development of novel...
November 28, 2023
Rakovina Therapeutics Inc (TSX-V:RKV) on Monday announced the appointment of Professor Artem Cherkasov to its Scientific Advisory Board (SAB). Cherkasov is...
September 6, 2023
While cancer tends to be more common in older people, the evidence suggests that cases among the under 50s have been rising in many parts of the world since the 1990s.
September 5, 2023
While cancer tends to be more common in older people, the evidence suggests that cases among the under 50s have been rising in many parts of the world since the 1990s.
February 22, 2022
Two new trials exploring this approach ― olaparib in the PROpel trial and niraparib in the MAGNITUDE trial –― had slightly different results.
November 30, 2021
With AI, Dr. Artem Cherkasov and researchers took 19 days not 10 years to review 40 billion compounds to find potential COVID-19 drugs
August 11, 2021
Press release content from PR Newswire. The AP news staff was not involved in its creation.
May 11, 2021
Article content Vancouver, British Columbia–(Newsfile Corp. – May 11, 2021) – Amphotericin B Technologies, Inc (“Amp B Tech” or the “Company”), a wholly-owned subsidiary of iCo Therapeutics, Inc. (TSXV: ICO) (“iCo”), announced today that two presentations related to research on the effectiveness of the Company’s Oral Amphotericin B formulation (“iCo 019”) on the SARS-Cov-2 virus have been accepted to the 2021 CSPS/PSJ/CC-CRS Joint Symposium – Pharmaceutical Sciences i...
May 11, 2021
(2) Vancouver, British Columbia--(Newsfile Corp. - May 11, 2021) - Amphotericin B Technologies, Inc ("Amp B Tech" or the "Company"), a wholly-owned subsidiary of iCo Therapeutics, Inc. (TSXV: ICO) ("iCo"), announced today that two presentations related to research on the effectiveness of the Companys Oral Amphotericin B formulation ("iCo 019") on the SARS-Cov-2 virus have been accepted to the 2021 CSPS/PSJ/CC-CRS Joint Symposium - Pharmaceutical Sciences in a Pandemic World. The Symposium wil...